The Beatson Institute for Cancer Research in Bearsden, Scotland, and Carestream Molecular Imaging have signed a five-year partnership agreement to support the development of preclinical imaging approaches in oncology using the Carestream Albira trimodal imaging system.
The Albira combines PET, SPECT and CT modalities in one platform, which provides the Beatson Institute with imaging technologies to support research into cancer cell behavior and the development of new therapeutic, diagnostic and prognostic tools, according to the Woodbridge, Conn.-based Carestream Molecular.
Research at the Beatson Institute relies on the use of advanced technologies, including transgenic cancer models and imaging technologies housed within the Beatson Advanced Imaging Resource (BAIR), which is a center for preclinical fluorescence molecular imaging.
With the addition of PET, SPECT and CT capabilities and the experience of SINAPSE, BAIR will now provide PET, SPECT and CT imaging for various research groups within the Beatson Institute, the West of Scotland Cancer Center and other collaborators. The immediate use of the Albira will be to support oncology studies centered on understanding the genetic basis of pancreatic, colon, breast and skin cancers and their response to treatment. The Albira system provides a 3D quantitative capability to study biological processes at the tissue and cellular level and will be used in various research studies.